Celea Therapeutics Will Present Phase 3 Trial Design for IPF & Key Insights from a Deupirfenidone Drug-Drug Interaction Study ...
MORRISVILLE, NC / ACCESS Newswire / August 25, 2026 / 374Water Inc. (NASDAQ:SCWO) ("374Water" or the "Company"), a leading ...
mRNA cancer vaccine Phase 3 win: Merck and Moderna announced August 19 that intismeran autogene cut melanoma recurrence risk ...
SELLAS Life Sciences (SLS) stock soars 255% YTD as Phase 3 AML trial hits critical milestone. Analysts set $10 target amid ...
The latest results give investors confidence in the drug's ability to be approved in another indication for which there are ...
EyePoint, Inc. is rated a Sell, citing unfavorable risk/reward and concerns about commercial relevance against ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its ...
DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 ...
Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an ...
Total revenue increases by 14% to CHF 119 million Operating profit increases by 32% to CHF 32 million and net profit by 77% to CHF 28 million ...
Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results